About this Research Topic
In oncology, the discovery and application of precision medicine and targeted therapies have significantly shifted the approach to managing gastrointestinal (GI) and genitourinary (GU) solid tumors. These tumor types are characterized by their intricacy and diversity, previously treated with broader, less specific methods. Recent shifts toward specific, personalized treatments are supported by groundbreaking integration of genomic profiling and molecular biology in clinical settings, which enhances our ability to diagnose, target, and treat these cancers more effectively. Advances have been made, yet further elucidation of these therapies' mechanisms and broader application is urgently needed to understand their full potential and limitations.
This Research Topic aims to advance the understanding and application of targeted therapies and precision medicine in treating GI and GU cancers. With a focus on innovative therapeutic agents such as tyrosine kinase inhibitors, immune checkpoint inhibitors, and emerging monoclonal antibodies, this issue endeavors to bridge the gap between experimental therapy and clinical success. The goal is to catalyze the translation of recent scientific insights into actionable, effective treatment practices that improve patient outcomes while reducing adverse effects.
Within the confines of precision oncology for GI and GU cancers, this topic is open to submissions focusing on:
o Genomic and molecular profiling techniques and their impacts
o Innovative targeted therapies and their integration into treatment protocols
o Evaluation of immune checkpoint inhibitors specific to GI and GU cancers
o Impact assessments from clinical trials and case studies
o Emerging markers and targets for personalized therapy
o Collaborative research efforts that enhance treatment efficacy
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
This Research Topic aims to advance the understanding and application of targeted therapies and precision medicine in treating GI and GU cancers. With a focus on innovative therapeutic agents such as tyrosine kinase inhibitors, immune checkpoint inhibitors, and emerging monoclonal antibodies, this issue endeavors to bridge the gap between experimental therapy and clinical success. The goal is to catalyze the translation of recent scientific insights into actionable, effective treatment practices that improve patient outcomes while reducing adverse effects.
Within the confines of precision oncology for GI and GU cancers, this topic is open to submissions focusing on:
o Genomic and molecular profiling techniques and their impacts
o Innovative targeted therapies and their integration into treatment protocols
o Evaluation of immune checkpoint inhibitors specific to GI and GU cancers
o Impact assessments from clinical trials and case studies
o Emerging markers and targets for personalized therapy
o Collaborative research efforts that enhance treatment efficacy
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords: Precision Medicine, Targeted Therapies, Gastrointestinal Cancers, Genitourinary Cancers, Genomic Profiling, Molecular Profiling, Tyrosine Kinase Inhibitors, Immune Checkpoint Inhibitors, Monoclonal Antibodies, Personalized Treatment
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
